[go: up one dir, main page]

LV14230A - Pharmaceutical composition for prevention and treatment of parkinson's disease - Google Patents

Pharmaceutical composition for prevention and treatment of parkinson's disease

Info

Publication number
LV14230A
LV14230A LVP-09-86A LV090086A LV14230A LV 14230 A LV14230 A LV 14230A LV 090086 A LV090086 A LV 090086A LV 14230 A LV14230 A LV 14230A
Authority
LV
Latvia
Prior art keywords
parkinson
disease
prevention
treatment
pharmaceutical composition
Prior art date
Application number
LVP-09-86A
Other languages
Latvian (lv)
Other versions
LV14230B (en
Inventor
Vija Kluša
Jolanta Pupure
Sergejs Isajevs
Juris Rumaks
Šimons Svirskis
Inga Šaicāne
Ivars KALVIŅŠ
Original Assignee
Latvijas Organiskās Sintēzes Institūts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Organiskās Sintēzes Institūts filed Critical Latvijas Organiskās Sintēzes Institūts
Priority to LVP-09-86A priority Critical patent/LV14230B/en
Priority to PCT/EP2010/002658 priority patent/WO2010124873A1/en
Publication of LV14230A publication Critical patent/LV14230A/en
Publication of LV14230B publication Critical patent/LV14230B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of Meldonium [3-(2,2,2-trimethylhydrazinium)propionate dihydrate] and its pharmaceutically acceptable salts for prevention and/or treatment of Parkinson痴 disease.
LVP-09-86A 2009-04-30 2009-04-30 Pharmaceutical Composite & Imacration for Parkinson's Disease & Imacration Prevention & ā rst ē š LV14230B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LVP-09-86A LV14230B (en) 2009-04-30 2009-04-30 Pharmaceutical Composite & Imacration for Parkinson's Disease & Imacration Prevention & ā rst ē š
PCT/EP2010/002658 WO2010124873A1 (en) 2009-04-30 2010-04-30 3- (2, 2, 2, trimethylhydrazunium) propionate dihydrate (meldomium) for treating parkinson' s disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-09-86A LV14230B (en) 2009-04-30 2009-04-30 Pharmaceutical Composite & Imacration for Parkinson's Disease & Imacration Prevention & ā rst ē š

Publications (2)

Publication Number Publication Date
LV14230A true LV14230A (en) 2010-11-20
LV14230B LV14230B (en) 2011-05-20

Family

ID=42651244

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-09-86A LV14230B (en) 2009-04-30 2009-04-30 Pharmaceutical Composite & Imacration for Parkinson's Disease & Imacration Prevention & ā rst ē š

Country Status (2)

Country Link
LV (1) LV14230B (en)
WO (1) WO2010124873A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000955A (en) * 2003-08-04 2006-03-30 Grindeks Jsc Meldonium salts, method of their preparation and pharmaceutical composition on their basis.

Also Published As

Publication number Publication date
WO2010124873A8 (en) 2011-03-31
LV14230B (en) 2011-05-20
WO2010124873A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX374396B (en) SUBLINGUAL FENTANYL SPRAY.
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MX2013006591A (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof.
WO2009017837A3 (en) Sublingual fentanyl spray
WO2008149382A8 (en) Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
MX2010008921A (en) Oxazolidinone derivatives.
PL2371853T3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
IN2012DN01233A (en)
MX2009010407A (en) Fluorinated derivatives of deferiprone.
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
MX2009003372A (en) Non-mucoadhesive film dosage forms.
IL216967B (en) 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives and use thereof for the treatment of diseases
MX2012007375A (en) 3-keto-n-propargyl-1-aminoindan.
MX2009004561A (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MX2009006327A (en) Heterocycle compounds and methods of use thereof.
MX2011011109A (en) Oral formulations of bendamustine.
MX2012013879A (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases.
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
IL210386A (en) Indole derivatives, pharmaceutical compositions comprising same and use thereof for preparing medicaments for the treatment or prevention of neurodegenerative diseases